Table II.
Completed phase iii trials studying adjuvant androgen deprivation therapy
| Reference | Pts (n) | Risk group | rt (Gy) | Hormonal therapy (ht) | Median follow-up (years) | Scheme (ht months) |
Timing of ht |
Local failure | Biochemical ned | Distant metastasis | Overall survival | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pre-rt (months) | rt (months) | Post-rt (months) | |||||||||||
| Pilepich et al., 199752 Pilepich et al., 200553 (rtog 8531) | 945 | High | 65–70 | pab | 7.6 | rt alone | (final week) | (indefinite) | 38 | 9 | 39 | 39 | |
| rt+ ht (indefinite) | 23 | 31 | 24 | 49 | |||||||||
| (10 years, p<0.05) | (10 years, p=0.0001) | (10 years, p=0.0001) | (10 years, p=0.002) | ||||||||||
| Bolla et al., 199754 Bolla et al., 200255 (eortc 22863) | 412 | High | 70 | pab | 5.5 | rt alone | 7 | 45 | 29 | 62 | |||
| rt + ht (36) | 2 | 34 | 1 | 76 | 10 | 78 | |||||||
| (5 years, p<0.05) | (5 years, p<0.05) | (5 years, p<0.05) | (5 years, p=0.00002) | ||||||||||
| Hanks et al., 200356 Horwitz et al., 200857 (rtog 9202) | 1554 | High | 70 | pab | 5.8 | rt + ht (4) | 2 | 2 | 22 | 32 | 23 | 51 | |
| rt + ht (24) | 2 | 2 | 24 | 12 | 48 | 15 | 54 | ||||||
| (10 years, p<0.05) | (10 years, p<0.05) | (10 years, p<0.05) | (10 years, p=0.36) | ||||||||||
| Laverdiere et al., 200441 (Quebec L-200) | 296 | Low (25%) | 66 | tab | 3.7 | rt + ht (5) | 3 | 2 | nr | 70 | nr | nr | |
| rt + ht (10) | 3 | 2 | 5 | 70 | |||||||||
| Intermediate (41%) | (4 years, p=0.55) | ||||||||||||
| High (34%) | |||||||||||||
Pts = patients; rt = radiation therapy; ned = no evidence of disease; pab = partial androgen blockade; tab = total androgen blockade; nr = not reported.